AUTHOR=Rivalta Beatrice , Amodio Donato , Giancotta Carmela , Santilli Veronica , Pacillo Lucia , Zangari Paola , Cotugno Nicola , Manno Emma Concetta , Finocchi Andrea , Bernardi Stefania , Colagrossi Luna , Gentile Leonarda , Russo Cristina , Perno Carlo Federico , Rossi Paolo , Cancrini Caterina , Palma Paolo 

TITLE=Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.891274

DOI=10.3389/fimmu.2022.891274

ISSN=1664-3224

ABSTRACT=<p>We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies’ good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.</p>